Garth Stevens, MD
Ophthalmology · Henrico, VANPI 1689741738
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,006, 3.5 times the $291 reported in 2019.
Across 106 payments — averaging $38.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$771
- Alcon$713
- Sun Pharmaceutical Industries Inc.$499
- Lensar, Inc.$428
- Glaukos Corporation$247
- Bausch & Lomb, A Division Of Bausch Health US, LLC$217
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$3,82895%
- Education$401%
- Gifts$1403%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $771 |
| Alcon | 15 | $713 |
| Sun Pharmaceutical Industries Inc. | 18 | $499 |
| Lensar, Inc. | 1 | $428 |
| Glaukos Corporation | 3 | $247 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $217 |
| Rxsight Inc | 3 | $171 |
| Aerie Pharmaceuticals, Inc. | 4 | $142 |
| Amgen | 1 | $114 |
| Carl Zeiss Meditec USA, Inc. | 1 | $110 |
| Bausch & Lomb Americas Inc. | 5 | $106 |
| Bausch Health US, LLC | 1 | $102 |
| Oyster Point Pharma, Inc. | 3 | $84 |
| Harrow Eye, LLC | 2 | $51 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Sight Sciences, Inc. | 3 | $48 |
| Thea Pharma Inc. | 2 | $44 |
| Novartis | 2 | $41 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
| Dompe US, Inc. | 1 | $26 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$428
- Clareon$244
- iDose$186
- ARGOS$141
- Hydrus Microstent$141
- XEN GLAUCOMA TREATMENT SYSTEM$136
- CEQUA$125
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$121
- Rhopressa$121
- Rocklatan$121
- SIMBRINZA$121
- Unity$116
- TEPEZZA$114
- CLARUS 500$110
- VUITY$102
How this compares
$4,034 in reported general payments places this provider in the 80th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 42 | $52,641 |
| RocklatanNetarsudil Mesylat/Latanoprost | 86 | $40,199 |
| Cyclosporine | 35 | $20,286 |
| Prednisolone Acetate | 549 | $18,010 |
| LumiganBimatoprost | 24 | $12,917 |
| Latanoprost | 1,148 | $9,427 |
| VyzultaLatanoprostene Bunod | 19 | $8,134 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $6,489 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $6,316 |
| Loteprednol Etabonate | 49 | $6,260 |
| Pilocarpine Hcl | 73 | $4,725 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 356 | $4,655 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 39 | $3,703 |
| Dorzolamide Hcl | 238 | $3,490 |
| Ketorolac Tromethamine | 148 | $3,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $771 | $71,87379 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $142 | $40,19986 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $106 | $8,13419 claims |
| AlconSimbrinza | $713 | $6,48913 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $217 | $6,26049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Henrico
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Leonard RappaportPortsmouth$85K
- Soheila RostamiReston$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.